The U.S. Food and Drug Administration approved AstraZeneca’s top-selling treatment Tagrisso for another type of lung cancer when diagnosed at an early stage.
https://www.pharmalive.com/wp-content/uploads/2020/10/tagrisso.jpg14552250Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2020-12-21 02:54:292020-12-21 11:29:59AstraZeneca’s Tagrisso gets broader U.S. FDA nod for lung cancer